These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9889801)

  • 1. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
    von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
    Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
    Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
    J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
    Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
    Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
    Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
    Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
    J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
    Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
    World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
    Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
    O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
    Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors].
    Ungefroren H; Voss M; Henne-Bruns D; Kremer B; Kalthoff H
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):63-7. PubMed ID: 14518214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological escape mechanisms in pancreatic carcinoma.
    Ungefroren H; Voss M; Bernstorff WV; Schmid A; Kremer B; Kalthoff H
    Ann N Y Acad Sci; 1999 Jun; 880():243-51. PubMed ID: 10415870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines.
    Rajashekhar G; Loganath A; Roy AC; Mongelli JM
    Gynecol Oncol; 2003 Oct; 91(1):101-11. PubMed ID: 14529668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
    Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
    J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas and Fas-ligand expression in human pancreatic cancer.
    Kornmann M; Ishiwata T; Kleeff J; Beger HG; Korc M
    Ann Surg; 2000 Mar; 231(3):368-79. PubMed ID: 10714630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
    Lewis NR; Pallis M; Russell NH
    Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.